Novartis

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment includes researching, distributing and selling patented pharmaceuticals. The Sandoz segment focuses on marketing finished dosage form medicines and intermediary products including active pharmaceutical ingredients. The Corporate segment is involved in group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Novartis AG (NYSE: NVS) has reported a core EPS of $1.56 in Q2 FY22 compared to $1.66 a year ago, beating the consensus of $1.52. Net sales were $12.78 billion, down 1% Y/Y or up 5% at constant currency (CC), missing the consensus of $13.01 billion.

Novartis Posts Mixed Q2 Earnings, Expects Improved Earnings At Sandoz

Swiss drugmaker Novartis said earnings at its Sandoz unit, the maker of cheap generic drugs that might be put up for sale, would likely be flat this year, no longer expecting a decline, and added the strategic review was progressing as planned.

Novartis no longer expects earnings decline at under-review Sandoz unit

Ad hoc announcement pursuant to Art. 53 LR

Novartis delivers continued strong momentum of key growth brands, progress on strategic initiatives and confirms FY'22 Group guidance

Los Angeles, California--(Newsfile Corp. - July 15, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Novartis AG ("Novartis" or "the Company") (NYSE: NVS) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Novartis announced on May 5, 2022, a "temporary, voluntary suspension of production...

INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in Novartis AG with Losses of $100,000 to Contact the Firm

LOS ANGELES--(BUSINESS WIRE)---- $NVS #NVS--The Schall Law Firm Encourages Investors in Novartis AG with Losses of $100,000 to Contact the Firm

INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Novartis AG with Losses of $100,000 to Contact the Firm

NEW YORK , July 13, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Novartis AG ("Novartis" or the "Company") (NYSE: NVS). Such investors are advised to contact Robert S.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Novartis AG - NVS

New York, New York--(Newsfile Corp. - July 11, 2022) - Pomerantz LLP is investigating claims on behalf of investors of Novartis AG ("Novartis" or the "Company") (NYSE: NVS). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Novartis and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors Novartis AG - NVS

The global pharmaceutical company, Novartis, released its first-ever integrated social impact report. The report connects sustainability goals and business objectives.

Novartis debuted its first integrated sustainability and finance report this year — more companies are likely to follow suit

Novartis is a leading global pharmaceutical company with a solid portfolio of drugs, a strong pipeline, and a focus on shareholder returns. It maintains strong profitability, giving it sufficient buffer to fund new drug development.

Novartis: A Safe Bear Market Value Buy Now Yielding 4%

The street consensus anticipates 7.71% net profit CAGR over the next 5 years. Targeted acquisition, a likely spinoff of Sandoz and $15B share buyback underscore the commitment of investing in the core business and returning excess capital to shareholders.

Novartis Is Awakening From Lethargy

Enbridge

Altria

This bear market has brought the worst first half for stocks since 1970. Market timing is proven to be the absolute worst strategy you can try, a 98% guaranteed road to underperformance or even financial ruin.

4 High-Yield Dividend Aristocrat Retirement Dream Stocks

Novartis' (NVS) anti-PD-1 monoclonal antibody, tislelizumab, significantly extends median overall survival in first-line advanced esophageal cancer combined with chemotherapy.

Novartis (NVS) Announces Positive Data on Oncology Drug

Basel, June 30, 2022 — Today Novartis announced results from the Phase III RATIONALE 306 trial showing tislelizumab plus chemotherapy significantly improved overall survival (OS) as a first-line treatment for adult patients with unresectable, locally advanced or metastatic esophageal squamous cell carcinoma (ESCC), regardless of PD-L1 status. Tislelizumab plus chemotherapy demonstrated a median OS of 17.2 months (CI, 15.8-20.1 months) versus 10.6 months (CI, 9.3-12.1 months) in patients receiving chemotherapy plus placebo and reduced the risk of death by 34% (hazard ratio=0.66; CI, 0.54-0.80, p

New Phase III data show Novartis tislelizumab significantly extended median overall survival by more than 6 months in first-line advanced esophageal cancer in combination with chemotherapy

Novartis AG (ADR) (NYSE:NVS) is planning to cut 8,000 jobs or more than 7% of the pharma giant's global workforce as part of a large restructuring programme. Some of the jobs will be transferred to the Czech Republic and India, and others, which will become redundant with the restructuring, will be eliminated, the company told its staff via email.

Novartis to axe 8,000 jobs, some will be transferred to India

AbbVie

Bristol-Myers

Johnson & Johnson

Merck

Pfizer

Seagen

Sanofi

AstraZeneca

Roche Holding AG

Investors who are sweating the loss of patent protection for some of Big Pharma's top-selling drugs should relax.

Investors Need Not Be Alarmed by Drug Patent Expirations

The pharmaceutical giant said about 1,400 roles in its Switzerland headquarters could be eliminated due to a restructuring plan.

Novartis Will Cut Up to 8,000 Jobs Under CEO's Shake-Up Plan

Swiss pharmaceutical group Novartis informed staff on Tuesday it plans to lay off more than one in 10 employees in Switzerland, the TagesAnzeiger newspaper reported in its online edition.

Novartis plans to cut up to 1,400 jobs in Switzerland - TagesAnzeiger

The CHMP recommends approval of Novartis' (NVS) Scemblix for treating adult patients with chronic myeloid leukemia. EU also approves label expansion of Cosentyx.

Novartis (NVS) Gets Positive CHMP Opinion for Scemblix in CML

Axsome Therapeutics

Walgreens

While individuals are fearing another pandemic, could health care stocks be a great addition to your watchlist?

Cheap Stocks To Buy Today? 3 Health Care Stocks For Your Watchlist

Basel, June 24, 2022 — Novartis today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion and recommended granting marketing authorization for Scemblix® (asciminib) for the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP), previously treated with two or more tyrosine kinase inhibitors (TKIs). If approved, Scemblix will be the first CML treatment in Europe that works by specifically targeting the ABL myristoyl pocket (also known as a STAMP inhibitor in scientific literature), representing an important therapeutic advancement for patients who experience intolerance and/or resistance to currently available TKI therapies1.

Novartis receives positive CHMP opinion for Scemblix®, a novel treatment for adult patients with chronic myeloid leukemia

Novartis (NVS) obtains regulatory approval for label expansion of Tafinlar + Mekinist and Tabrecta.

Novartis' (NVS) Oncology Drugs Get Approval for Label Expansion

British American Tobacco

Diageo

Imperial Brands PLC

Well, that didn't last long. As we suspected, each and every market rally until the Federal Reserve completes the interest rate hike cycle likely will be met with selling as investors try to go to cash and get away from the market's downward spiral.

Why These 5 European Dividend Aristocrats (Some With Huge Yields) Are Incredible Q3 Buys

Basel, June 23, 2022 — Novartis endorses the Kigali Declaration on neglected tropical diseases (NTDs) and announces a five-year financial commitment of USD 250 million to the fight against NTDs and malaria in conjunction with the Kigali Summit on Malaria and NTDs alongside the 26th Commonwealth Heads of Government (CHOGM) meeting. This summit comes at a pivotal time for world leaders to reaffirm commitments to end neglected tropical diseases and malaria through the adoption of the Kigali Declaration. The declaration aims to mobilize political will and secure commitments to achieve the SDG3 target on NTDs and to deliver the targets set out in the World Health Organization's Neglected Tropical Disease Roadmap (2021-2030).

Novartis renews commitment to neglected tropical disease and malaria elimination, investing USD 250 million over five years to research and develop new treatments

Basel, June 23, 2022 — Novartis today announced the US Food and Drug Administration (FDA) granted accelerated approval for Tafinlar® (dabrafenib) + Mekinist® (trametinib) for the treatment of adult and pediatric patients 6 years of age and older with unresectable or metastatic solid tumors with BRAF V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options1,2. In accordance with the Accelerated Approval Program, continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). Tafinlar + Mekinist is the first and only BRAF/MEK inhibitor to be approved with a tumor-agnostic indication for solid tumors carrying the BRAF V600E mutation, which drives tumor growth in more than 20 different tumor types, and it is the only BRAF/MEK inhibitor approved for use in pediatric patients1,2.

Novartis Tafinlar + Mekinist receives FDA approval for first tumor-agnostic indication for BRAF V600E solid tumors

Precision Biosciences

DTIL stock is advancing in early trading today after Precision BioScience announced a partnership with Novartis, a leading drug maker. The post Precision BioSciences (DTIL) Stock Treks Higher on Novartis Deal appeared first on InvestorPlace.

News for Novartis Stock (NVS)